<DOC>
	<DOCNO>NCT02996682</DOCNO>
	<brief_summary>The primary objective study evaluate antiviral efficacy , safety , tolerability sofosbuvir/velpatasvir ( SOF/VEL ) fixed-dose combination ( FDC ) without ribavirin ( RBV ) 12 week adults chronic HCV infection decompensated cirrhosis .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir/Velpatasvir Â± Ribavirin 12 Weeks Adults With Chronic HCV Infection Decompensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Key Chronic HCVinfected male nonpregnant/nonlactating female Treatment naive treatment experienced individual ChildPughTurcotte Score 712 screen Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Communicable Diseases</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Decompensated Cirrhosis</keyword>
</DOC>